Despite promising results in preclinical investigations [168], erlotinib, which is another EGFR tyrosine kinase inhibitor (TKI), exhibited poor efficacy and unacceptable side effects [169] in phase 2 clinical trials of newly diagnosed or recurrent GBM patients. Here, EGFR is linked to glioblastoma.